Companies · Biotechnology

Nature's Toolbox, Inc.

RIO RANCHO · Biotechnology

Diligence memoA one-page analyst read on Nature's Toolbox, Inc. — recommendation, valuation, rhythm, risks.
$82.0M
Total raised · real
5
Rounds
1.0×
Latest step-up
Top 13%
Sector rank · raised
Series C
Latest stage · inferred · Wed Nov 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Nature's Toolbox, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.28× the median modeled value of Series C Biotechnology companies in 2025–2027 (58 peers) — value vs value, same stage and era.
Active
  • Last raise 7 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Nature's Toolbox, Inc. is one of 4293 Biotechnology companies tracked from RIO RANCHO. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
19
Investors (latest)
2025-11-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2020-01-02 Raised $13M (real) Modeled valuation $469M (est)$13M$469MSeries A2020Series A · 2023-08-25 Raised $10M (real) Modeled valuation $80M (est)$10M$80MSeries A2023Series C · 2023-11-07 Raised $44M (real) Modeled valuation $507M (est)$44M$507MSeries C2023Series C · 2025-05-09 Raised $4.2M (real) Modeled valuation $27M (est)$4.2M$27MSeries C2025Series C · 2025-11-19 Raised $10M (real) Modeled valuation $55M (est)$10M$55MSeries C2025Series A · 2025-11-19 Raised $10.0M (real) Modeled valuation $27M (est)$10.0M$27MSeries A2025+$10M+$44M+$4.2M+$10M+$10.0MCumulative $92M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$13.0M · 2020
Series A extension$10.1M · 2023
Series C$44.4M · 2023no Series B on file
Series C extension$4.2M · 2025
Series C extension$10.4M · 2025
Bridge · Series C-stage$10.0M · 2025smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$54.5M
Base estimate est.
$32.1M
Conservative case
$68.5M
Upside case
$69.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $468.9M · 2020-01-022020Series A · modeled $79.7M · 2023-08-25Series C · modeled $507.2M · 2023-11-07Series C · modeled $27.1M · 2025-05-09Series C · modeled $54.5M · 2025-11-19Series A · modeled $26.8M · 2025-11-192025
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
0.6 yr
Elapsed time used
0.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$13.9M/yr
Capital velocity
6.5 yr
On record since
2020
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 11× above median
This company$82.0M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.2× of median
This company$10.0M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 0.8× of median
This company$54.5M
Sector median$64.2M

Raised more than 88% of sector peers (real $). Modeled value above 47% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #44 of 58.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)Newleos Therapeutics, Inc. · Series C Raised $93.4M · modeled $659.9M (est)Biolinq Inc · Series C Raised $247.4M · modeled $619.1M (est)Atsena Therapeutics, Inc. · Series C Raised $146.0M · modeled $606.4M (est)Galvanize Therapeutics, Inc. · Series C Raised $150.7M · modeled $582.3M (est)X4 Pharmaceuticals, Inc · Series C Raised $320.3M · modeled $495.3M (est)Endless Corp · Series C Raised $79.0M · modeled $494.3M (est)Ikena Oncology, Inc. · Series C Raised $117.6M · modeled $449.1M (est)Imbria Pharmaceuticals, Inc. · Series C Raised $140.2M · modeled $406.0M (est)Bambusa Therapeutics, Inc. · Series C Raised $67.4M · modeled $375.4M (est)Plexium, Inc. · Series C Raised $60.1M · modeled $361.5M (est)Latigo Biotherapeutics, Inc. · Series C Raised $50.0M · modeled $357.9M (est)Neuros Medical, Inc. · Series C Raised $160.0M · modeled $338.5M (est)Nature's Toolbox, Inc. (this company) Raised $82.0M · modeled $54.5M (est)Nature's Toolbox, Inc.
CompanyStageRaised · realValue · estvs peer med.
Newleos Therapeutics, Inc.Series C$93.4M$659.9M3.43×
Biolinq IncSeries C$247.4M$619.1M3.22×
Atsena Therapeutics, Inc.Series C$146.0M$606.4M3.15×
Galvanize Therapeutics, Inc.Series C$150.7M$582.3M3.03×
X4 Pharmaceuticals, IncSeries C$320.3M$495.3M2.57×
Endless CorpSeries C$79.0M$494.3M2.57×
Ikena Oncology, Inc.Series C$117.6M$449.1M2.33×
Imbria Pharmaceuticals, Inc.Series C$140.2M$406.0M2.11×
Bambusa Therapeutics, Inc.Series C$67.4M$375.4M1.95×
Plexium, Inc.Series C$60.1M$361.5M1.88×
Latigo Biotherapeutics, Inc.Series C$50.0M$357.9M1.86×
Neuros Medical, Inc.Series C$160.0M$338.5M1.76×
Nature's Toolbox, Inc. this companySeries C$82.0M$54.5M0.28×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$13.0M2020-01-02$59.0M$468.9M90%
Series A$10.1M2023-08-25$45.7M$79.7M90%
Series C$44.4M2023-11-07$296.0M$507.2M90%
Series C$4.2M2025-05-09$28.0M$27.1M90%
Series C$10.4M2025-11-19$69.1M$54.5M90%
Series A$10.0M2025-11-19$45.3M$26.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$13.0M2020-01-02
    • First recorded raise — entered as Series A.
    • 39 investors on this round.
  2. Series A$10.1M2023-08-25
    • Raised again after 44 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 32 investors on this round.
  3. Series C$44.4M2023-11-07
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
    • 19 investors on this round.
  4. Series C$4.2M2025-05-09
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round 10.6× smaller than the prior — bridge or down round.
    • 14 investors on this round.
  5. Series C$10.4M2025-11-19
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 19 investors on this round.
  6. Series A$10.0M2025-11-19
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 19 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~14mo cadence
$10.0M
Modeled next size est.range $10.0M$15.9M
1.0×
Last step-up
$13.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Peter Kolchinsky7 other2025-05
Edward M. Liddy2 other2023-08
David R. Johnson1 other2025-05
Thomas R. Nickoloff1 other2020-01
Alexander Koglin2020-01
Alexander M. Koglin2023-11
Andrew M Weber2023-08
Charles M. McMillan2023-08
Daniel R. Clark2025-11
David R. Seldin2020-01
Edward R. Liddy2025-05
James Coffin2025-05
James M. Coffin2023-08
James R. Coffin2025-11
Joan Haab2025-11
Marcel R. Roche2023-11
Michael Humbert2020-01
Michael M. Humbert2023-11
Nancy M Rurkowski2023-08
Peter M. Kolchinsky2023-11
Registry & provenance

Nature's Toolbox, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1798793
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Vaxess Technologies, Inc.BiotechnologySeries C$138.2M$270.2Mnetwork1 shared operator · same sector · same stage
Iliad Biotechnologies, LlcBiotechnologySeries C$98.3M$52.1Msame sector · same stage
Virtual Incision CorpBiotechnologySeries C$100.8M$53.9Msame sector · same stage
Character Biosciences, Inc.BiotechnologySeries C$57.0M$50.5Msame sector · same stage
Neonc Technologies Holdings, Inc.BiotechnologySeries C$121.6M$51.9Msame sector · same stage
Scipher Medicine CorpBiotechnologySeries C$123.0M$55.5Msame sector · same stage
ImmunoGenesis, Inc.BiotechnologySeries C$50.2M$43.0Msame sector · same stage
ARS Pharmaceuticals, Inc.PharmaceuticalsSeries C$63.0M$1.3Bnetwork1 shared operator · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Brainbox Solutions, Inc.BiotechnologySeries B$67.8M88%
Arbor Biotechnologies, Inc.BiotechnologySeries D+$5.7B87%
Parcel Biosciences, Inc.BiotechnologySeries A$32.0M87%
Locus Biosciences, Inc.BiotechnologySeries B$213.3M86%
BiomeSense, Inc.BiotechnologySeries A$22.4M86%
Shoreline Biosciences, Inc.BiotechnologySeries D+$3.7B86%
Willow Biosciences Inc.BiotechnologySeed$43.3M86%
Intuitive Biosciences, Inc.BiotechnologySeed$54.3M86%
Frequently asked
How much funding has Nature's Toolbox, Inc. raised?
Nature's Toolbox, Inc. has raised approximately $82.0M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Nature's Toolbox, Inc.'s estimated valuation?
Provath's modeled valuation for Nature's Toolbox, Inc. is approximately $54.5M (modeled range $32.1M–$68.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Nature's Toolbox, Inc. at?
Nature's Toolbox, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Nov 19.
What does Nature's Toolbox, Inc. do and where is it based?
Nature's Toolbox, Inc. operates in the Biotechnology sector, based in RIO RANCHO.
Explore related

See where Nature's Toolbox, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Nature's Toolbox, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.